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Abstract
Introduction/Aim. Lung cancer is a leading cause of
mortality among patients with carcinomas. The aim of this
study was to point out risk factors for brain metastases
(BM) appearance in patients with IIIA (N2) stage of non-
small cell lung cancer (NSCLC) treated with three-modal
therapy. Methods. We analyzed data obtained from 107
patients with IIIA (N2) stage of NSCLC treated surgically
with neoadjuvant therapy. The frequency of brain metasta-
ses was examined regarding age, sex, histological type and
the size of tumor, nodal status, the sequence of radiother-
apy and chemotherapy application and the type of che-
motherapy.  Results. Two and 3-year incidence rates of
BM were 35% and 46%, respectively. Forty-six percent of
the patients recurred in the brain as their first failure in the
period of three years. Histologically, the patients with
nonsquamous cell lung carcinoma had significantly higher
frequency of metastases in the brain compared with the
group of squamous cell lung carcinoma (46%  :  30%;
p  =  0.021). Examining treatment-related parameters,
treatment with taxane-platinum containing regimens was
associated with a lower risk of brain metastases, than
platinum-etoposide chemotherapy regimens (31%  :  52%;
p  =  0.011). Preoperative radiotherapy, with or without
postoperative treatment, showed lower rate of metastases in
the brain compared with postoperative radiotherapy treat-
ment only (33% : 48%; p = 0.035). Conclusion. Brain me-
tastases are often site of recurrence in patients with NSCLC
(IIIA-N2). Autonomous risk factors for brain metastases in
this group of patients are non-squamous NSCLC, N1-N2
nodal status, postoperative radiotherapy without preopera-
tive radiotherapy.
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Apstrakt
Uvod/Cilj. Karcinom pluća vodeći je uzrok mortaliteta
među obolelima od malignih bolesti. Cilj ove studije bio
je da se ukaže na faktore rizika od pojave metastaza u
mozgu kod bolesnika sa stadijumom IIIA (N2) nemikro-
celularnog karcinoma (non-small cell lung cancer – NSCLC)
lečenih trimodalitetnom terapijom. Metode. Analizirani
su podaci 107 bolesnika sa stadijumom IIIA (N2)
NSCLC lečenih hirurški uz dodatnu neoadjuvantnu tera-
piju. Učestalost metastaza u mozgu ispitivana je u zavis-
nosti od starosti, pola, histološkog tipa i veličine tumora,
nodalnog statusa, redosleda primene zračne i hemiotera-
pije i vrste hemioterapije. Rezultati. Dvogodišnja i 3-
godišnja incidencija moždanih metastaza iznosila je 35% i
46%, respektivno. Četrdeset i šest procenata bolesnika
imalo je metastaze u mozgu kao prvo mesto relapsa u
trogodišnjem periodu. Histološki, bolesnici sa neskva-
mocelularnim karcinomom pluća imali su značajno veću
učestalost metastaza u mozgu u odnosu na grupu skva-
mocelularnih karcinoma (46%  :  31%; p = 0,021).  Ispiti-
vanjem terapijskih parametara, lečenje bolesnika prime-
nom režima koji uključuju taksane i platinu bilo je pove-
zano sa nižim rizikom od pojave metastaza u mozgu uStrana 644 VOJNOSANITETSKI PREGLED Volumen 68, Broj 8
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odnosu na etoposid-cisplatin režim (31%  :  52%;
p = 0,011). Bolesnici koji su preoperativno zračeni, sa ili
bez postoperativne zračne terapije, imali su nižu stopu
metastaza u mozgu u odnosu na one koji su lečeni samo
postoperativnom zračnom terapijom (33%  :  48%;
p = 0,035). Zaključak. Metastaze u mozgu često su me-
sto relapsa kod bolesnika sa NSCLC (IIIA-N2). Nezavis-
ni faktori rizika od pojave metastaza u mozgu u ovoj
grupi bolesnika su neskvamocelularni karcinom, nodalni
status N1-N2 i postoperativna zračna terapija bez preo-
perativne zračne terapije.
Ključne reči:
pluća, nesitnoćelijski karcinom; neoplazme, metastaze;
mozak; lečenje kombinovanjem antineoplastika,
protokoli; radioterapija; faktori rizika.
Introduction
In patients with lung cancer metastases frequently occur
in the brain. Around 20%–40% of patients with non-small
cell lung cancer (NSCLC) develop brain metastases. The
frequency of brain metastases in NSCLC is smaller than in
small-cell lung cancer (SCLC), but their occurrence after
treatment possess a big problem. Brain metastases in NSCLC
attract attention because combined modalities of treatment
bring progress in local control and overall survival rate
among patients with NSCLC. With the increase of survival
rate after combined modalities of treatment it can be noticed
that the frequency of brain metastases is still increasing 
1–3.
Big studies on NSCLC show increased risk from distant
metastases, especially brain ones, after treatment has been
completed. Andre et al. 
2 in a retrospective study including
clinical N2 patients, surgically treated with or without
neoadjuvant therapy, have shown that overall frequency of
brain metastases is 32% and 18%, respectively  (p < 0.05).
Ceresoli et al. 
3 have shown that among patients with stage
III NSCLC, treated with combined modalities of therapy, the
brain has been the primary spot of relapse in 23% of the pa-
tients, and total of 50% of the patients have developed brain
metastases in the further course of the disease.
Approximately 40,000 patients a year in the world are
diagnosed with locally advanced, non-metastatic NSCLC
(stage III). Patients with diagnosed IIIA stage of NSCLC
belong to pretty wide varieties of different subgroups: some
of them have favorable outcomes, such as patients with lo-
cally invasive tumor (T3) and hilar and/or peribronchial
nodes (N1) or microscopically with N2 disease, and others
groups have less than favorable outcomes, such as patients
with bulky mediastinal adenopathy 
4.
Nowadays priority treatment for the patients with stage
IIIA is controversial. Some centers apply chemotherapy with
full dose of radiation therapy without surgery, while others
recommend surgery as an independent treatment or after
neoadjuvant chemotherapy together with competitive radia-
tion therapy or without it. Independent surgery is possible in
10%–40% patients with stage IIIA, depending on patient se-
lection and the degree of lymph node involvement. Surgical
treatment includes resection (lobectomy and pneumonec-
tomy) and analysis of mediastinal lymph glands (mediastinal
mapping). Complete dissection of lymph glands should be
performed if the carcinoma is resectable and if mediastinal
lymph glands are involved. However, even though carci-
noma may be resectable in stage IIIA with N2 there is usu-
ally no use of surgical treatment. There is a clear biological
difference when carcinoma is coinciding with N2 disease in
comparison to N1 subcategory 
5. With patients in N2 sub-
stage of stage III only surgical treatment is considered (se-
lected patients) and its expediency. In the last 30 years, many
studies have been exploring the role of multi-modality ap-
proach in treatment of locally advanced NSCLC, that consist
of combination of loco-regional surgical therapy and/or ra-
diation therapy and systemic chemotherapy. Most of trials 
6–
10, but not all of them 
11, 12, suggest preoperative induction
chemotherapy due to better control of the disease and in-
crease of survival rate. Combined chemotherapy, together
with surgical and radiation therapy, can reduce the occur-
rence of brain metastases in patients with stage IIIA of
NSCLC, and it can also improve the quality of life and sur-
vival expectancy.
The aim of this study was to present the risk factors for
brain metastases occurrence in patients with stage IIIA of
NSCLC, after completed surgical, radiation and chemother-
apy.
Methods
The research involved 107 patients with NSCLC, IIIA
stage of the disease, who underwent lung resection in the pe-
riod from 1999 to 2008, in the Centre for Toracal Surgery of
the Clinical Center Kragujevac, Institute for Pulmonary Dis-
ease of the Clinical Center of Serbia in  Belgrade and the
Clinic for Toracal Surgery of the Military Medical Academy,
Belgrade. Histopathological confirmation of the disease was
performed on tissue samples using standard hematoxylin and
eosine (H&E) staining method. Histologically confirmed
NSCLC was classified as stadium IIIA according to the
TNM classification. The analysis included only the patients
that had pulmonary resection and received preoperational
therapy after mediastinoscopy. Most patients received
neoadjuvant chemotherapy, radiation therapy or both mo-
dalities. The decision on the type of therapy depended on the
size of the tumor, nodal status and patient’s performance
status. Preoperative chemotherapy was indicated in patients
with IIIA (N2) stage of NSCLC, good performance status
and minimal lymph nodes (< 1.5 cm), as well as in patients
with bordering performance status (PS-2, ECOG scale) with
lymph nodes size 1.5–3 cm. Patients in good physical state
with N2 status (1.5–3 cm, bulky) received combined chemo
and radiation therapy as induction therapy. Decision on the
type of chemotherapy depended on the attitude of oncologi-
cal consortium for lungs of the institution where the treat-
ment was performed. Characteristics of tested patients (gen-Volumen 68, Broj 8 VOJNOSANITETSKI PREGLED Strana 645
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der, age, performance status, histological type of cancer) did
not vary for different types of chemotherapy.
All patients that received preoperational therapy prior to
surgical treatment of the lungs had to repeat CT of the chest
and upper abdomen for the purpose of testing the progress of
the disease. Computed tomography of central nervous system
(CNS) was performed on each of the patients before the lung
treatment.
Post-treatment screening was performed in all of the
patients who had signs or symptoms of CNS ailment such as:
defects of visual field, nausea, vomiting, motoric and sense
dysfunctions, dysfunction of cranial nerves, new headaches,
confusion or convulsions. Identification of brain metastases
in most of the patients was performed by using computed
tomography of CNS, only a few underwent magnetic reso-
nance imaging. Other metastases were confirmed with CT of
the chest or abdomen, via ultrasound of abdomen or scintig-
raphy of skeletal system. All patients with good performance
status (0–2, ECOG scale) with confirmed metastases in CNS
underwent radiation therapy of CNS. Patients with confirmed
metastases of other localizations and good physical condition
continued the treatment with secondary chemotherapy ac-
cording to docetaxel-cisplatin protocol.
After the treatment of primary lung cancer had been
completed, the risk of brain metastases was estimated, treat-
ing brain as the first place of relapse or relapse in further
course of the disease.
Following factors were estimated using univariate
analysis to determine the possible risk оf appearance of brain
metastases: age, gender, histological type, tumor size, nodal
status, chronology of application of radiation therapy, che-
motherapy and the type of chemotherapy. Log-rank test was
used for univariate analysis. Proportional hazard regression
model was used for multivariate analysis and identification
of independent prognostic factors.
Pearson’s chi-square test was used for statistical analy-
sis, as well as univariate and multivariate analysis. Statisti-
cally significant value was p < 0.05.
Results
Demographic characteristics and variables analyzed in
examined group of patients are shown in Table 1. There were
107 patients in examined group (64 men and 43 women);
their average age was 61 (range from 37 to 73 year). Most of
examined patients had squamous cell lung carcinoma
(50.5%).
Most of primary lung tumor resections consisted of lo-
bectomy (61.5%), and pneumonectomy (27%) (Table 2).
Postoperative death rate was 2.8 % and determined number
of deaths within 30 days since the operation. Chemotherapy
according to the paclitaxel and cisplatin protocol, received
38% of the patients. Twenty nine (27%) patients received
preoperative radiotherapy, 38% postoperative, while 12% of
the patients received preoperative and postoperative radio-
therapy (Table 2). Out of total number of patients, 72 (67%)
received combined chemo and radiotherapy as a beginning of
the disease initial treatment.
Out of 107 NSCLC treated patients, 44% had metastasis
in the brain in the third year after the treatment was finished.
Risk factors for appearance of metastases in the brain, ex-
amined with univariate analysis, are shown in Table 3. Pa-
tients with non-squamous cell lung carcinoma had signifi-
cantly higher incidence of metastases in the brain within 3-
year period compared to those with squamous cell carcinoma
(46% : 31%; p = 0.021). The treatment with chemotherapy ac-
cording to paclitaxel and cisplatin protocol was connected with
lower brain metastases incidence within 3-year period, com-
pared with that including chemotherapy according to the eto-
poside-cisplatin protocol (31% : 52%; p = 0.011) (Table 3).
Table 1
Characteristics of the examined patients with NSCLC
Characteristics n %
Total number of patients 107 100
Gender
male 64 60
female 43 40
Average age (range), years 61 (37–73)
Histological type
squamous cell 54 50,5
adenocarcinoma 48 45
bronchialveolar 1 1
large cell 4 3,5
Tumor status, postoperative
T0 10 9,5
T1 34 32
T2 45 42
T3 11 10
T4 7 6,5
Nodal status, postoperative
N0 33 31
N1 24 22
N2 50 47Strana 646 VOJNOSANITETSKI PREGLED Volumen 68, Broj 8
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Preoperative radiotherapy with postoperative therapy or
without it, showed lower rate of metastases in the brain,
compared with just postoperative therapy within period of
three years (33% : 48%; p = 0.035) (Table 3).
Within 3-year period, incidence of metastases in the
brain of patients with N0 status was significantly lower than
that in the N1-N2 group (31% : 49%; p < 0.001) (Table 3).
Risk factors for occurrence of metastases in the brain,
as a first site of relapse after the treatment was finished, ex-
amined by univariate analysis, were: histological type, nodal
status, type of chemotherapy and radiotherapy order (table
4). Patients with squamous cell lung carcinoma compared to
those with nonsquamous cell carcinoma (32%  :  44%;
p = 0.033), as well as patients treated with preoperative ra-
diotherapy compared to those just postoperative treated with
radiotherapy  (33% : 48%;  p  =  0.065), have lower rate of
brain metastases in the 3-years period (Table 4).
Multivariate analysis showed that autonomous risk
factors for brain metastases after finished treatment were:
nonsquamous cell lung carcinoma (p < 0.01),  nodal  status
(p < 0.001) and the order of radiotherapy use (p < 0.01).
Analysis of metastases incidence in the brain of patients with
NSCLC in relation to histological type and nodal status showed
that non-squamous cell carcinoma with N1-N2 nodal status had
significantly higher one-year (32%), two-year (51%) and three-
year incidence compared to that in patients with squamous cell
carcinoma and N1-N2 status (p = 0.002) (Table 5).
With univariate analysis we examined which of the risk
factors for brain metastases affected the survival length of
examined patients (Table 6). Age, tumor size, nodal status
Table 2
Treatment of the examined patients with non-small cell lung cancer (NSCLC)
Treatment n %
Total number of patients 107 100
Surgical approach
lobectomia 66 61,5
pneumonectomia 29 27
bilobectomia 6 5,5
segmentectomia 3 3
other 3 3
Chemotherapy
etoposide and cisplatin 52 49
paclitaxel and cisplatin 41 38
other, postoperative 1 1
without therapy 13 12
Neoadjuvant and adjuvant therapy
tri-modality 72 67
chemotherapy and surgery 15 14
radiation therapy and surgery 17 16
no therapy 3 3
Table 3
Risk factors for brain metastases
Risk factors (%) Variables One year Two-year Three-year p
Patients (total number of patients 107; died 68) 20 33 49
Gender
male 19 35 48
female 22 39 52 0,652
Age (years)
≤ 60 18 37 39
> 60 16 48 49 0,535
Tumor status, postoperative
T0-T1 19 36 37
T2-T4 21 44 47 0,652
Nodal status, postoperative
N0 18 29 31
N1-N2 31 45 49 < 0,001
Histological type
squamous cell 15 28 35
non-squamous cell 32 43 46 0,021
Chronology of radiotherapy
pre ± postoperative 17 27 33
only postoperative 29 42 48 0,035
Chemotherapy
etoposide and cisplatin 19 26 31
paclitaxel and cisplatin 32 44 52 0,011Volumen 68, Broj 8 VOJNOSANITETSKI PREGLED Strana 647
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Table 4
Incidence rate of meatastases in the brain as first relapse
Incidence of brain metastases (%) Variables One year Two-year Three-year p
Patients (total number of patients 107; died 68) 17 35 46
Gender
male 17 32 45
female 21 35 49 0.405
Age (years)
≤ 60 17 34 33
> 60 16 41 42 0.462
Tumor status, postoperative
T0-T1 16 32 34
T2-T4 19 41 45 0.538
Nodal status, postoperative
N0 16 25 28
N1-N2 27 41 45 0.015
Histological type
squamous cell 12 24 32
non-squamous cell 28 39 44 0.033
Chronology of radiotherapy
pre ± postoperative 15 25 31
only postoperative 26 40 45 0.069
Chemotherapy
etoposide and cisplatin 17 24 29
paclitaxel and cisplatin 30 41 48 0.023
Table 5
Incidence rate of metastases in the brain in relation to histological type
 and nodal (N) status
Incidence of brain metastases (%) Histology and N status One year Two-year Three-year p
Squamous cell, N0 14 24 29
Non-squamous cell, N0 19 29 32
Squamous cell, N1-N2 20 29 35
Non-squamous cell, N1-N2 32 51 59
 0.002
Table 6
Prognostic factors for patients with stage IIIA of non-small cell lung cancer (NSCLC)
Survival (%) Variables Average period of survival
(months) One year Two-year Three-year p
Patients (total number of patients 107; died 68) 25 74 52 41
Gender
male 30 76 58 46
female 27 72 54 43 0.231
Age (years)
≤ 60 23.6 73 58 36
> 60 15.3 47 33 24 < 0.001
Tumor status, postoperative
T0-T1 27.9 79 58 46
T2-T4 17.6 64 45 28 < 0.001
Nodal status, postoperative
N0 37.1 85 68 57
N1-N2 19.5 69 48 31 < 0.001
Histological type
squamous cell 28.2 80 54 43
non-squamous cell 23.7 70 49 36 0.351
Chronology of radiotherapy
pre ± postoperative 29.4 77 55 48
only postoperative 25.3 76 54 37 0.674
Chemotherapy
etoposide and cisplatin 36.6 88 70 49
paclitaxel and cisplatin 19.2 69 34 27 < 0.001Strana 648 VOJNOSANITETSKI PREGLED Volumen 68, Broj 8
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and the type of chemotherapy were all significant factors in
the group of patients with IIIA stage of NSCLC (Table 6).
Three-year survival rate was significantly higher in the
group of patients aged  60 (36%) (p < 0.001), with tumor
size T0-T1 (46%) (p  <  0.001) and nodal status N0 (57%)
(p < 0.001), compared to that in the group of patients older
than 60 years, with tumor size T2-T4 (28%) and nodal status
N1-N2 (31%) (Table 6).
In the group of patients who received chemotherapy ac-
cording to the protocol paclitaxel-cisplatin, 2-year (70%) and
3-year survival rate (49%) was significantly higher compared
with the patients received combination cisplatin- etoposid
(p < 0.001) (Table 6).
Discussion
We analyzed the patients with IIIA (N2) stage of
NSCLC treated with multimodal therapy, including surgery,
radiotherapy and chemotherapy. All the patients in this study
were surgically treated, and the biggest number of them
were, before thoracotomy, subjected to mediastinoscopy and
biopsy of lymph nodes. ESMO recommendations from 2009
suggest that preoperative chemotherapy based on cisplatin
can be considered in patients with IIIA-N2 stage 
13. In the
last 10–15 years most of phase II trials suggest that neoadju-
vant chemotherapy with radiotherapy or without it, can im-
prove surgical respectability, controlling the disease and sur-
vival rate at the stage IIIA N2 NSCLC 
14–17. Recent studies
point out that aggressive chemo and radiotherapy can signifi-
cantly reduce even the incidence of metastases in CNS in
patients with IIIA stage, especially in three-modality therapy
18, 19. Randomized studies and meta-analyses support the
conclusion that combined treatment, which includes chemo-
therapy on the basis of platinum preparations, improves sur-
vival compared with radiotherapy only 
19, 20.
Most common chemotherapy protocols at the end of 20th
century implied the inclusion of the protocols based on plati-
num. Results of our analysis showed higher rate of 3-year sur-
vival in the group of patients who received protocols with ta-
xane (46%) in comparison with that in the group of patients
who received protocols without taxane (25%) (p < 0.001).
Aggressive approach to the primary tumor with three-
modality therapy results also in a low rate of loco-regional
recurrence with 14%. Although this result was better than the
results that are achieved with only chemo or radiotherapy,
most trials with definite chemo and radiotherapy are limited
only to patients with non-resectable tumor and commonly to
combined patients with IIIA i IIIB diseases 
21–23. Despite this,
three-year survival in our analysis was just 40%, due to high
percent of distant metastases, primarily in the brain. Forty-
nine percent of our patients developed metastases in the
brain in the three-year period (46% as the first site of re-
lapse). The obtained results are compatible with the data
from the literature 
1, 2, 18, 23–25.
Moreover, results are consistent with the earlier reports,
which have shown increased incidence of brain metastases in
patients with non-squamous cell carcinoma 
11, 19, 20, 25–27. In
univariate analysis, nodal status, after the induction therapy,
and also a type of chemotherapy showed significant connec-
tion to decrease of brain metastases.
Robnett et al. 
28 have shown that the delay of radio or
chemotherapy, with surgery as the initial treatment, increases
the incidence of brain metastases. Our results are similar to
these data in which preoperative radiotherapy, compared
with postoperative one is associated with a tendency to re-
duce the risk for metastases occurrence in the brain.
In SCLC incidence of metastases in the brain is higher
than in NSCLC, and meta-analysis of seven randomized tri-
als suggests prophylactic radiotherapy of endocranium as a
progress in reducing brain metastases incidence and overall
survival inprovement 
29–32. Some trials have shown that pro-
phylactic brain radiotherapy in NSCLC affects decreasing
the incidence of brain metastases, but not the overall survival
33. Notwithstanding the fact that brain metastases are still a
major problem of morbidity and death rate in patients with
NSCLC, Radiation Therapy Oncology Group has now given
a priority to randomized phase III with prophylactic radio-
therapy in patients with IIIA stage of NSCLC. In our analy-
sis, we identified a subgroup of patients with NSCLC (pa-
tients with residual nodal glands after neoadjuvant therapy
and non-squamous cell histologic type) which have shown
high risk for the occurrence of brain metastases. Results con-
firm other data that metastatic disease is, primarily of CNS,
bigger and more significant problem than local disease in
patients with IIIA stage of NSCLC. For that reason, im-
proving the survival will require also the improvement of
systematic therapy, in which prophylactic radiotherapy can
be an integral part of, as an addition to systematic chemo-
therapy which lowers the risk of extracranial metastases, but
not metastases in the brain 
24.
Conclusion
Metastases in the brain are frequent site of relapse in
patients with NSCLC (IIIA-N2). Autonomous risk factors for
brain metastases in this group of patients are non-squamous
cell lung carcinoma, N1-N2 nodal status and postoperative
radiotherapy without preoperative radiotherapy.
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